 Neelanjan Mukherjee
Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA-Binding Proteins | 13 | 2023 | 371 | 2.640 |
Why?
| | RNA, Messenger | 14 | 2021 | 2657 | 1.750 |
Why?
| | RNA | 8 | 2023 | 833 | 1.720 |
Why?
| | Transcriptome | 7 | 2021 | 756 | 1.270 |
Why?
| | Gene Expression Regulation | 7 | 2019 | 2445 | 0.870 |
Why?
| | Aldosterone | 1 | 2021 | 43 | 0.820 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2021 | 152 | 0.770 |
Why?
| | RNA, Ribosomal | 1 | 2021 | 158 | 0.760 |
Why?
| | Ribonucleoproteins | 3 | 2019 | 88 | 0.750 |
Why?
| | ELAV-Like Protein 1 | 6 | 2021 | 20 | 0.670 |
Why?
| | Antigens, Surface | 3 | 2011 | 156 | 0.560 |
Why?
| | HEK293 Cells | 8 | 2019 | 625 | 0.560 |
Why?
| | RNA, Untranslated | 1 | 2016 | 115 | 0.520 |
Why?
| | Tristetraprolin | 1 | 2014 | 6 | 0.490 |
Why?
| | RNA Processing, Post-Transcriptional | 2 | 2011 | 84 | 0.470 |
Why?
| | Gene Expression Profiling | 5 | 2016 | 1597 | 0.460 |
Why?
| | Sequence Analysis, RNA | 6 | 2019 | 409 | 0.450 |
Why?
| | RNA Stability | 1 | 2011 | 97 | 0.380 |
Why?
| | RNA Precursors | 1 | 2011 | 136 | 0.370 |
Why?
| | Binding Sites | 6 | 2019 | 1224 | 0.370 |
Why?
| | MicroRNAs | 6 | 2019 | 637 | 0.320 |
Why?
| | Computational Biology | 4 | 2018 | 588 | 0.280 |
Why?
| | Lymphocyte Activation | 1 | 2009 | 1067 | 0.260 |
Why?
| | T-Lymphocytes | 2 | 2009 | 1774 | 0.250 |
Why?
| | Immunoprecipitation | 3 | 2014 | 161 | 0.240 |
Why?
| | ELAV Proteins | 3 | 2011 | 17 | 0.210 |
Why?
| | 3' Untranslated Regions | 2 | 2021 | 142 | 0.210 |
Why?
| | Ribosomes | 2 | 2015 | 142 | 0.200 |
Why?
| | Argonaute Proteins | 2 | 2019 | 28 | 0.200 |
Why?
| | Angiotensin II | 1 | 2021 | 107 | 0.200 |
Why?
| | Software | 3 | 2018 | 613 | 0.190 |
Why?
| | Molecular Sequence Annotation | 2 | 2019 | 91 | 0.190 |
Why?
| | Interferons | 1 | 2021 | 151 | 0.190 |
Why?
| | Hydrocortisone | 1 | 2021 | 273 | 0.180 |
Why?
| | Proteome | 1 | 2023 | 353 | 0.180 |
Why?
| | Herpesvirus 8, Human | 2 | 2011 | 68 | 0.180 |
Why?
| | Open Reading Frames | 2 | 2016 | 121 | 0.170 |
Why?
| | Humans | 23 | 2021 | 118972 | 0.170 |
Why?
| | Drosophila melanogaster | 2 | 2019 | 200 | 0.170 |
Why?
| | Nucleotide Motifs | 1 | 2018 | 31 | 0.170 |
Why?
| | Base Sequence | 3 | 2019 | 2159 | 0.170 |
Why?
| | RNA Splicing | 2 | 2017 | 243 | 0.160 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 554 | 0.160 |
Why?
| | Gene Expression | 2 | 2016 | 1489 | 0.160 |
Why?
| | RNA, Antisense | 2 | 2019 | 19 | 0.160 |
Why?
| | Drosophila Proteins | 1 | 2019 | 171 | 0.150 |
Why?
| | DEAD-box RNA Helicases | 1 | 2017 | 56 | 0.150 |
Why?
| | RNA, Long Noncoding | 1 | 2019 | 161 | 0.150 |
Why?
| | Protein Biosynthesis | 3 | 2015 | 397 | 0.140 |
Why?
| | RNA, Viral | 2 | 2011 | 572 | 0.140 |
Why?
| | Neoplasm Proteins | 2 | 2017 | 401 | 0.130 |
Why?
| | Cells, Cultured | 2 | 2021 | 4077 | 0.130 |
Why?
| | Phenotype | 1 | 2023 | 3003 | 0.130 |
Why?
| | DNA Damage | 1 | 2017 | 357 | 0.130 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 564 | 0.130 |
Why?
| | RNA, Plant | 1 | 2013 | 9 | 0.120 |
Why?
| | Genome, Human | 1 | 2016 | 387 | 0.120 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2014 | 138 | 0.120 |
Why?
| | Regulatory Sequences, Ribonucleic Acid | 1 | 2012 | 18 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2010 | 770 | 0.110 |
Why?
| | Arabidopsis | 1 | 2013 | 69 | 0.110 |
Why?
| | Protein Interaction Mapping | 1 | 2013 | 104 | 0.110 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2012 | 65 | 0.110 |
Why?
| | Lymphoma, Primary Effusion | 1 | 2011 | 3 | 0.110 |
Why?
| | Nanoparticles | 1 | 2016 | 325 | 0.100 |
Why?
| | Transcription, Genetic | 2 | 2019 | 1323 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1167 | 0.100 |
Why?
| | Amino Acid Motifs | 1 | 2011 | 200 | 0.100 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 420 | 0.100 |
Why?
| | Nuclear Factor 90 Proteins | 1 | 2010 | 1 | 0.100 |
Why?
| | Poly(A)-Binding Proteins | 1 | 2009 | 5 | 0.090 |
Why?
| | Stilbenes | 1 | 2009 | 35 | 0.090 |
Why?
| | Jurkat Cells | 1 | 2009 | 134 | 0.090 |
Why?
| | Cell Proliferation | 1 | 2016 | 2275 | 0.080 |
Why?
| | Thymus Gland | 1 | 2009 | 300 | 0.080 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2007 | 155 | 0.080 |
Why?
| | Cell Line, Tumor | 5 | 2016 | 2851 | 0.070 |
Why?
| | Kinetics | 1 | 2009 | 1624 | 0.070 |
Why?
| | Algorithms | 1 | 2013 | 1541 | 0.070 |
Why?
| | rho GTP-Binding Proteins | 1 | 2006 | 65 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2017 | 1965 | 0.070 |
Why?
| | Radiation Tolerance | 1 | 2006 | 98 | 0.060 |
Why?
| | Polyadenylation | 2 | 2017 | 38 | 0.060 |
Why?
| | Adenoviridae | 1 | 2005 | 191 | 0.060 |
Why?
| | Neoplasm Invasiveness | 1 | 2006 | 462 | 0.060 |
Why?
| | Paclitaxel | 1 | 2005 | 195 | 0.060 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2005 | 180 | 0.060 |
Why?
| | Microtubule-Associated Proteins | 1 | 2005 | 188 | 0.060 |
Why?
| | Molecular Sequence Data | 3 | 2014 | 2871 | 0.060 |
Why?
| | Cell Line | 3 | 2019 | 2707 | 0.060 |
Why?
| | Glioblastoma | 1 | 2006 | 262 | 0.060 |
Why?
| | Animals | 10 | 2019 | 33381 | 0.060 |
Why?
| | Multigene Family | 2 | 2014 | 200 | 0.060 |
Why?
| | RNA Interference | 2 | 2016 | 460 | 0.050 |
Why?
| | Signal Transduction | 3 | 2016 | 4709 | 0.050 |
Why?
| | Mice | 6 | 2016 | 15520 | 0.050 |
Why?
| | Evolution, Molecular | 2 | 2019 | 454 | 0.050 |
Why?
| | Substrate Specificity | 2 | 2012 | 371 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 982 | 0.040 |
Why?
| | Introns | 1 | 2019 | 234 | 0.040 |
Why?
| | Prostatic Neoplasms | 1 | 2005 | 940 | 0.040 |
Why?
| | Brain Neoplasms | 1 | 2006 | 1022 | 0.040 |
Why?
| | Radiation, Ionizing | 1 | 2017 | 74 | 0.040 |
Why?
| | In Vitro Techniques | 2 | 2010 | 1094 | 0.030 |
Why?
| | DNA Repair | 1 | 2017 | 198 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 239 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2017 | 874 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2016 | 334 | 0.030 |
Why?
| | Heterozygote | 1 | 2016 | 262 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2014 | 372 | 0.030 |
Why?
| | Plant Roots | 1 | 2013 | 39 | 0.030 |
Why?
| | Systems Integration | 1 | 2013 | 42 | 0.030 |
Why?
| | Gene Expression Regulation, Plant | 1 | 2013 | 45 | 0.030 |
Why?
| | Genome, Plant | 1 | 2013 | 45 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2016 | 306 | 0.030 |
Why?
| | Epigenomics | 1 | 2013 | 107 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2013 | 336 | 0.030 |
Why?
| | Response Elements | 1 | 2012 | 82 | 0.030 |
Why?
| | Child Development Disorders, Pervasive | 1 | 2012 | 61 | 0.030 |
Why?
| | Cross-Linking Reagents | 1 | 2012 | 186 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2013 | 193 | 0.030 |
Why?
| | Signal-To-Noise Ratio | 1 | 2011 | 59 | 0.030 |
Why?
| | Data Interpretation, Statistical | 1 | 2013 | 336 | 0.030 |
Why?
| | Ovary | 1 | 2012 | 205 | 0.020 |
Why?
| | Macaca | 1 | 2010 | 54 | 0.020 |
Why?
| | Regulon | 1 | 2010 | 31 | 0.020 |
Why?
| | Operon | 1 | 2010 | 62 | 0.020 |
Why?
| | Eukaryotic Cells | 1 | 2010 | 34 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2014 | 2071 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2011 | 253 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 307 | 0.020 |
Why?
| | Receptors, Death Domain | 1 | 2009 | 4 | 0.020 |
Why?
| | Brain | 2 | 2012 | 2490 | 0.020 |
Why?
| | Chromatin | 1 | 2013 | 441 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2010 | 410 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2010 | 345 | 0.020 |
Why?
| | Linear Models | 1 | 2011 | 827 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 3588 | 0.020 |
Why?
| | Female | 4 | 2017 | 61564 | 0.020 |
Why?
| | Protein Binding | 1 | 2014 | 1975 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2011 | 453 | 0.020 |
Why?
| | Fanconi Anemia Complementation Group Proteins | 1 | 2007 | 9 | 0.020 |
Why?
| | Cell Transformation, Viral | 1 | 2007 | 22 | 0.020 |
Why?
| | Chemokines | 1 | 2009 | 230 | 0.020 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2007 | 40 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2008 | 219 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2007 | 193 | 0.020 |
Why?
| | Species Specificity | 1 | 2008 | 565 | 0.020 |
Why?
| | HeLa Cells | 1 | 2008 | 583 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 4908 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2006 | 59 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2013 | 2874 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 2006 | 245 | 0.020 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2005 | 44 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2009 | 565 | 0.020 |
Why?
| | Stem Cells | 1 | 2009 | 559 | 0.020 |
Why?
| | Caspases | 1 | 2005 | 269 | 0.020 |
Why?
| | Saccharomyces cerevisiae | 1 | 2008 | 495 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2006 | 341 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2006 | 828 | 0.010 |
Why?
| | Genetic Therapy | 1 | 2005 | 267 | 0.010 |
Why?
| | Mice, Nude | 1 | 2005 | 663 | 0.010 |
Why?
| | Transfection | 1 | 2006 | 888 | 0.010 |
Why?
| | Blotting, Western | 1 | 2006 | 1194 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2007 | 770 | 0.010 |
Why?
| | ErbB Receptors | 1 | 2006 | 569 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 3457 | 0.010 |
Why?
| | Up-Regulation | 1 | 2005 | 872 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2009 | 1753 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2008 | 1178 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2005 | 671 | 0.010 |
Why?
| | Models, Biological | 1 | 2008 | 1715 | 0.010 |
Why?
| | Male | 3 | 2014 | 57801 | 0.010 |
Why?
| | Rats | 1 | 2006 | 5392 | 0.010 |
Why?
| | Apoptosis | 1 | 2005 | 2484 | 0.010 |
Why?
| | Child | 1 | 2012 | 19129 | 0.010 |
Why?
| | Adult | 1 | 2014 | 31512 | 0.010 |
Why?
|
|
Mukherjee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|